DK3607962T3 - Angiotensin ii alene eller i kombination til behandlingen af hypotension - Google Patents

Angiotensin ii alene eller i kombination til behandlingen af hypotension

Info

Publication number
DK3607962T3
DK3607962T3 DK19197866.7T DK19197866T DK3607962T3 DK 3607962 T3 DK3607962 T3 DK 3607962T3 DK 19197866 T DK19197866 T DK 19197866T DK 3607962 T3 DK3607962 T3 DK 3607962T3
Authority
DK
Denmark
Prior art keywords
hypotension
angiotensin
alone
treatment
combination
Prior art date
Application number
DK19197866.7T
Other languages
Danish (da)
English (en)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3607962(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington Univ A Congressionally Chartered Not For Profit Corporation filed Critical The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Application granted granted Critical
Publication of DK3607962T3 publication Critical patent/DK3607962T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19197866.7T 2013-12-18 2014-12-18 Angiotensin ii alene eller i kombination til behandlingen af hypotension DK3607962T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19
EP14872684.7A EP2986308B1 (en) 2013-12-18 2014-12-18 Angiotensin ii in combination for the treatment of hypotension

Publications (1)

Publication Number Publication Date
DK3607962T3 true DK3607962T3 (da) 2025-11-17

Family

ID=53367119

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19197866.7T DK3607962T3 (da) 2013-12-18 2014-12-18 Angiotensin ii alene eller i kombination til behandlingen af hypotension
DK14872684.7T DK2986308T3 (en) 2013-12-18 2014-12-18 Angiotensin ii i kombination til behandlingen af hypotension

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14872684.7T DK2986308T3 (en) 2013-12-18 2014-12-18 Angiotensin ii i kombination til behandlingen af hypotension

Country Status (25)

Country Link
US (7) US9220745B2 (enExample)
EP (2) EP2986308B1 (enExample)
JP (4) JP6824739B2 (enExample)
KR (4) KR102399383B1 (enExample)
CN (4) CN106061493A (enExample)
AU (3) AU2014364528C1 (enExample)
BR (1) BR112016013961A2 (enExample)
CA (1) CA2933601A1 (enExample)
CY (1) CY1122604T1 (enExample)
DK (2) DK3607962T3 (enExample)
EA (1) EA037823B1 (enExample)
ES (1) ES2771749T3 (enExample)
FI (1) FI3607962T3 (enExample)
HR (1) HRP20200009T1 (enExample)
HU (1) HUE047062T2 (enExample)
IL (1) IL246162B (enExample)
LT (2) LT3607962T (enExample)
MX (2) MX380968B (enExample)
NZ (1) NZ721089A (enExample)
PL (1) PL2986308T3 (enExample)
PT (2) PT3607962T (enExample)
RS (1) RS59804B1 (enExample)
SI (1) SI2986308T1 (enExample)
SM (2) SMT202000018T1 (enExample)
WO (1) WO2015095535A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
US9220745B2 (en) 2013-12-18 2015-12-29 The George Washington University, a Congressionally Not-for-Profit Corporation Angiotensin II alone or in combination for the treatment of hypotension
KR20170026486A (ko) * 2014-07-08 2017-03-08 라 졸라 파마슈티칼 컴파니 저혈압 치료 방법
US9919022B2 (en) 2015-03-20 2018-03-20 Arthur J. ATKINSON, JR. Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
WO2017120440A1 (en) * 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) * 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto
US20250366467A1 (en) * 2022-06-15 2025-12-04 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
WO2024129057A1 (en) * 2022-12-12 2024-06-20 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
EP1401864A1 (en) 2001-06-04 2004-03-31 Human Genome Sciences Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP2007510643A (ja) 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
DE602006021600D1 (de) 2005-09-29 2011-06-09 Fibrogen Inc Verfahren zur senkung des blutdrucks
AU2006332449B2 (en) 2005-12-30 2008-05-15 Howard Florey Institute Of Experimental Physiology And Medicine A method of treatment
WO2007146900A2 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
CA2678131A1 (en) 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
AU2009319856A1 (en) 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
BR112013000744A2 (pt) 2010-07-14 2020-07-14 Cumberland Emerging Technologies, Inc uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas
AU2014256944B2 (en) 2013-04-26 2019-06-27 La Jolla Pharma, Llc Compositions and methods for treating renal failure
US9220745B2 (en) 2013-12-18 2015-12-29 The George Washington University, a Congressionally Not-for-Profit Corporation Angiotensin II alone or in combination for the treatment of hypotension
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
KR20170026486A (ko) 2014-07-08 2017-03-08 라 졸라 파마슈티칼 컴파니 저혈압 치료 방법
WO2017120440A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto

Also Published As

Publication number Publication date
KR20220028125A (ko) 2022-03-08
KR20240154702A (ko) 2024-10-25
US11559559B2 (en) 2023-01-24
JP6824739B2 (ja) 2021-02-03
CA2933601A1 (en) 2015-06-25
DK2986308T3 (en) 2020-01-27
KR20160117437A (ko) 2016-10-10
US11096983B2 (en) 2021-08-24
AU2014364528A1 (en) 2016-06-30
US20180193407A1 (en) 2018-07-12
EP3607962B1 (en) 2025-08-13
MX380968B (es) 2025-03-12
AU2014364528C1 (en) 2021-01-07
NZ721089A (en) 2022-10-28
AU2014364528B2 (en) 2020-08-27
US9220745B2 (en) 2015-12-29
MX2020011190A (es) 2020-11-13
AU2020277230A1 (en) 2020-12-24
US10493124B2 (en) 2019-12-03
WO2015095535A1 (en) 2015-06-25
FI3607962T3 (fi) 2025-11-24
RS59804B1 (sr) 2020-02-28
KR20230051721A (ko) 2023-04-18
JP2017501154A (ja) 2017-01-12
AU2024219851A1 (en) 2024-10-10
JP2019214610A (ja) 2019-12-19
KR102399383B1 (ko) 2022-05-19
CN119700926A (zh) 2025-03-28
HRP20200009T1 (hr) 2020-03-20
JP7175506B2 (ja) 2022-11-21
CN112546197A (zh) 2021-03-26
BR112016013961A2 (pt) 2017-10-10
AU2014364528A9 (en) 2016-07-28
EA037823B1 (ru) 2021-05-25
HUE047062T2 (hu) 2020-04-28
EP3607962A1 (en) 2020-02-12
SMT202000018T1 (it) 2020-03-13
JP2022137224A (ja) 2022-09-21
CN106061493A (zh) 2016-10-26
JP2025114753A (ja) 2025-08-05
US20190070250A1 (en) 2019-03-07
US20230226141A1 (en) 2023-07-20
LT2986308T (lt) 2020-03-25
PT2986308T (pt) 2020-01-21
US10765722B2 (en) 2020-09-08
CY1122604T1 (el) 2021-03-12
CN111920939A (zh) 2020-11-13
EP2986308B1 (en) 2019-10-16
EP2986308A1 (en) 2016-02-24
MX2016008108A (es) 2017-03-09
US10028995B2 (en) 2018-07-24
US20150164980A1 (en) 2015-06-18
US20220047669A1 (en) 2022-02-17
IL246162B (en) 2020-03-31
IL246162A0 (en) 2016-07-31
ES2771749T3 (es) 2020-07-07
SMT202500427T1 (it) 2026-01-12
LT3607962T (lt) 2026-01-12
US20160129072A1 (en) 2016-05-12
SI2986308T1 (sl) 2020-03-31
PT3607962T (pt) 2025-11-18
WO2015095535A9 (en) 2016-07-14
US20190328827A1 (en) 2019-10-31
EP2986308A4 (en) 2017-01-11
EA201691258A1 (ru) 2016-11-30
PL2986308T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
IL280908B (en) Combination therapy with neoantigen vaccine
DK3607962T3 (da) Angiotensin ii alene eller i kombination til behandlingen af hypotension
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
IL240845A0 (en) Compounds and uses thereof for the modulation of hemoglobin
EP3057691A4 (en) PLASMA-TREATED POLYMER MEMBRANES
BR302013005965S1 (pt) Configuração aplicada em otomana
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis
DK2984184T3 (da) Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer
DK2947323T3 (da) Spiralhuspumpe
DK3071192T3 (da) Curcuphenolforbindelse til anvendelse i behandling af cancer
BR302013005862S1 (pt) Configuração aplicada em coador
DK3209889T3 (da) Forbedringer i eller angående forbindelsesindretninger
BR302014001901S1 (pt) Configuração aplicada em organizador
DK2976089T3 (da) Anvendelse af sedoheptulose til forebyggelse eller behandling af inflammation
DK2994171T3 (da) Havvandstransport til anvendelse i carbonhydrid-relaterede processser
PL2999886T3 (pl) Zastosowanie systemu pompowego
DK3093053T3 (da) Klaringstank i ét stykke
ES1078754Y (es) Trampa capturadora de avispas en colmenas
BR302013002068S1 (pt) Configuração aplicada em esguicho.
UA26249S (uk) Водяний насос
UA26248S (uk) Водяний насос
BR302013002839S1 (pt) Configuração aplicada em tanque
FI10319U1 (fi) Sovitelma saunan lauteissa
CO6801681A2 (es) Surtidor